Predictors of clinical outcome in patients with heparin-induced thrombocytopenia treated with direct thrombin inhibition

Blood Coagulation and Fibrinolysis

Volumn 19, Issue 6, 2008, Pages 471-475

  Kelton, John G ^a   Hursting, Marcie J ^b   Heddle, Nancy ^a   Lewis, Bruce E ^c  

^a MCMASTER UNIVERSITY   (Canada)

^b Clinical Science Consulting   (United States)

^c LOYOLA UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

Argatroban; Direct thrombin inhibitor; Heparin induced thrombocytopenia; Platelets; Risk factors; Thrombosis

Indexed keywords

ARGATROBAN; HEPARIN; THROMBIN INHIBITOR; THROMBIN;

ADULT; ADVERSE OUTCOME; AGED; AMPUTATION; ARTICLE; CARDIOVASCULAR SURGERY; CLINICAL TRIAL; CONTINUOUS INFUSION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DEATH; DRUG SUBSTITUTION; DRUG WITHDRAWAL; FEMALE; HEPARIN INDUCED THROMBOCYTOPENIA; HIGH RISK PATIENT; HUMAN; KIDNEY DISEASE; KIDNEY DYSFUNCTION; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; OUTCOME ASSESSMENT; PRIORITY JOURNAL; PROGNOSIS; RISK ASSESSMENT; RISK FACTOR; THROMBOCYTE COUNT; THROMBOCYTOPENIA; THROMBOSIS; CARDIOVASCULAR DISEASE; CHEMICALLY INDUCED DISORDER; COMORBIDITY; DRUG ANTAGONISM; HOSPITALIZATION; IDIOPATHIC THROMBOCYTOPENIC PURPURA; MIDDLE AGED; MORTALITY; POSTOPERATIVE COMPLICATION; PROSPECTIVE STUDY; RECURRENT DISEASE; STATISTICS; TREATMENT OUTCOME;

AGED; AMPUTATION; CARDIOVASCULAR DISEASES; COMORBIDITY; FEMALE; HEPARIN; HUMANS; KIDNEY DISEASES; MALE; MIDDLE AGED; MULTICENTER STUDIES AS TOPIC; PLATELET COUNT; POSTOPERATIVE COMPLICATIONS; PROSPECTIVE STUDIES; PURPURA, THROMBOCYTOPENIC, IDIOPATHIC; RECURRENCE; RISK FACTORS; SEVERITY OF ILLNESS INDEX; THROMBIN; THROMBOSIS; TREATMENT OUTCOME;

EID: 58149115520     PISSN: 09575235     EISSN: None     Source Type: Journal    
DOI: 10.1097/MBC.0b013e3282a167cc     Document Type: Article

References (27)

1. Warkentin TE, Sheppard JI, Horsewood P, Simpson PJ, Moore JC, Kelton JG. Impact of the patient population on the risk for heparin-induced thrombocytopenia. Blood 2000; 96:1703-1708.
2. Warkentin TE, Hayward CPM, Boshkov LK, Santos AV, Sheppard JA, Bode AP, Kelton JG. Sera from patients with heparin-induced thrombocytopenia generate platelet-derived microparticles with procoagulant activity: an explanation for the thrombotic complications of heparin-induced thrombocytopenia. Blood 1994; 84:3691-3699.
3. Kelton JG. The pathophysiology of heparin-induced thrombocytopenia. Biological basis for treatment. Chest 2005; 127:9S-20S.
4. Warkentin TE, Kelton JG. Temporal aspects of heparin-induced thrombocytopenia. N Engl J Med 2001; 344:1286-1292.
5. Warkentin TE, Kelton JG. Delayed-onset heparin-induced thrombocytopenia and thrombosis. Ann Intern Med 2001; 135:502-506.
6. Hirsh J, Heddle N, Kelton JG. Treatment of heparin-induced thrombocytopenia: a critical review. Arch Intern Med 2004; 164:361-369.
7. Jang IK, Hursting MJ. When heparin promote thrombosis: reviewofheparin-induced thrombocytopenia. Circulation 2005; 111:2671-2683.
8. Warkentin TE, Greinacher A. Heparin-induced thrombocytopenia: recognition, treatment, and prevention. Chest 2004; 126:311S-337S.
9. Lewis BE, Wallis DE, Berkowitz SD, Matthai WH, Fareed J, Walenga JM, et al. Argatroban anticoagulant therapy in patients with heparin-induced thrombocytopenia. Circulation 2001; 103:1838-1843.
10. Lewis BE, Wallis DE, Leya F, Hursting MJ. Kelton JG, for the Argatroban-915 investigators. Argatroban anticoagulation in patients with heparin-induced thrombocytopenia. Arch Int Med 2003; 163:1849- 1856.
11. Greinacher A, Völpel H, Janssens U, Hach-Wunderle V, Kemkes-Matthes B, Eichler P, et al. Recombinant hirudin (lepirudin) provides safe and effective anticoagulation in patients with heparin-induced thrombocytopenia: a prospective study. Circulation 1999; 99:73-80.
12. Greinacher A, Janssens U, Berg G, Hach-Wunderle V, Kemkes-Matthes B, Eichler P, et al. Lepirudin (recombinant hirudin) for parenteral anticoagulation in patients with heparin-induced thrombocytopenia. Circulation 1999; 100:587-593.
13. Lubenow N, Eichler P, Lietz T, Greinacher A. Lepirudin in patients with heparin-induced thrombocytopenia - results of the third prospective study (HAT-3) and a combined analysis of HAT-1, HAT-2, and HAT-3. J Thromb Haemost 2005; 3:2428-2436.
14. Carlsson LE, Lubenow N, Blumentritt C, Kempf R, Papenberg S, Schoder W, et al. Platelet receptor and clotting factor polymorphisms as genetic risk factors for thromboembolic complications in heparin-induced thrombocytopenia. Pharmacogenetics 2003; 13:253-258.
15. LaMonte MP, Brown PM, Hursting MJ. Stroke in patients with heparin-induced thrombocytopenia and the effect of argatroban therapy. Crit Care Med 2004; 32:976-980.
16. Lewis BE, Wallis DE, Hursting MJ, Levine RL, Leya F. Effects of argatroban therapy, demographic variables, and platelet count on thrombotic risks in heparin-induced thrombocytopenia. Chest 2006; 129:1407-1416.
17. Fabris F, Luzzatto G, Soini B, Ramon R, Scandellari R, Randi ML, et al. Risk factors for thrombosis in patients with immune mediated heparin-induced thrombocytopenia. J Intern Med 2002; 252:149-154.
18. Greinacher A, Farner B, Kroll H, Kohlmann T, Warkentin TE, Eichler P. Clinical features of heparin-induced thrombocytopenia including risk factors for thrombosis. Thromb Haemost 2005; 94:132-135.
19. Opatrny L, Warner MN. Risk of thrombosis in patients with malignancy and heparin-induced thrombocytopenia. Am J Hematol 2004; 76:240-244.
20. Zwicker JI, Uhl L, Huang WY, Shaz BH, Bauer KA. Thrombosis and ELISA optical density values in hospitalized patients with heparin-induced thrombocytopenia. J Thromb Haemost 2004; 2:2133-2137.
21. Wallis DE, Workman DL, Lewis BE, Steen L, Pifarre R, Moran JF. Failure of early heparin cessation as treatment for heparin-induced thrombocytopenia. Am J Med 1999; 106:629-635.
22. Nand S, Wong W, Yuen B, Yetter A, Schmulbach E, Fisher SG. Heparin-induced thrombocytopenia with thrombosis: incidence, analysis of risk factors, and clinical outcomes in 108 consecutive patients treated at a single institution. Am J Hematol 1997; 56:12-16.
23. Boshkov LK, Warkentin TW, Hayward CPM, Andrew M, Kelton JG. Heparin-induced thrombocytopenia and thrombosis: clinical and laboratory studies. Br J Hematol 1993; 84:322-328.
24. Frame JN. The heparin-induced thrombocytopenia task force model: implementing quality improvement and economic outcome initiatives. Semin Hematol 2005; 42:S28-S35.
25. McMullough PA, Soman SS, Shah SS, Smith ST, Marks KR, Yee J, Borzak S. Risks associated with renal dysfunction in patients in the coronary care unit. J Am Coll Cardiol 2000; 36:679-684.
26. Shmuely H, Pitlik S, Drucker M, Samra Z, Konisberger H, Leibovici L. Prediction of mortality in patients with bacteremia: the importance of preexisting renal insufficiency. Ren Fail 2000; 22:99-108.
27. Schiavon M, DiLandro D, Baldo M, DeSilvestro G, Chiarelli A. A study of renal damage in seriously burned patients. Burns Incl Therm Inj 1988; 14: 107-112.